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Background: Rasmussen encephalitis (RE) is a rare neuroinflammatory disease characterized by intractable seizures
and progressive atrophy on one side of the cerebrum. Perivascular cuffing and clusters of T cells in the affected
cortical hemisphere are indicative of an active cellular immune response.
Methods: Peripheral blood mononuclear cells (PBMCs) and brain-infiltrating lymphocytes (BILs) were isolated from
20 RE surgery specimens by standard methods, and CD3+ T cell populations were analyzed by flow cytometry.
Gamma delta T cell receptor spectratyping was carried out by nested PCR of reversed transcribed RNA extracted
from RE brain tissue, followed by high resolution capillary electrophoresis. A MiSeq DNA sequencing platform was
used to sequence the third complementarity determining region (CDR3) of δ1 chains.
Results: CD3+ BILs from all of the RE brain specimens comprised both αβ and γδ T cells. The median αβ:γδ ratio
was 1.9 (range 0.58–5.2) compared with a median ratio of 7.7 (range 2.7–40.8) in peripheral blood from the same
patients. The αβ T cells isolated from brain tissue were predominantly CD8+, and the majority of γδ T cells were
CD4− CD8−. Staining for the early activation marker CD69 showed that a fraction of the αβ and γδ T cells in the
BILs were activated (median 42 %; range 13–91 %, and median 47 %; range 14–99 %, respectively). Spectratyping
T cell receptor (TCR) Vδ1-3 chains from 14 of the RE brain tissue specimens indicated that the γδ T cell repertoire
was relatively restricted. Sequencing δ1 chain PCR fragments revealed that the same prevalent CDR3 sequences
were found in all of the brain specimens. These CDR3 sequences were also detected in brain tissue from 15 focal
cortical dysplasia (FCD) cases.
Conclusion: Neuroinflammation in RE involves both activated αβ and γδ T cells. The presence of γδ T cells with
identical TCR δ1 chain CDR3 sequences in all of the brain specimens examined suggests that a non-major
histocompatibility complex (MHC)-restricted immune response to the same antigen(s) is involved in the etiology of
RE. The presence of the same δ1 clones in CD brain implies the involvement of a common inflammatory pathway
in both diseases.
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Rasmussen encephalitis (RE) is a rare pediatric neuro-
logical disease with an estimated incidence in children
under the age 18 years of 2–3 per 10 million [1–3]. The
acute phase of the disease is characterized by intense un-
controlled partial or generalized seizures, and MRI
FLAIR imaging often shows inflammation in one cere-
bral hemisphere [3]. As the disease progresses, unilateral
loss of cerebral tissue leaves the patient with severe
hemiparesis and other neurological deficits. Corticoste-
roids may provide short term benefit but ultimately fail
to halt the disease. Early treatment with tacrolimus or
intravenous immunoglobulins may stabilize the neuro-
logical deterioration, but they do not reverse the intract-
able epilepsy [2]. An inflammatory response involving T
cells and activated microglia confined to the affected
hemisphere appears to be the cause of the clinical symp-
toms. However, what precipitates the immune response
is not known. Several types of Herpesviridae have been
detected in surgical brain specimens from RE patients;
however, to date, there is no consistent evidence for a
pathogen that is common to all RE cases [4–7]. Likewise,
autoantibodies have been described in RE cases indica-
tive of an autoimmune disease, but autoantibodies have
not been found in all RE cases [8–11].
The observation of polarized granzyme B-containing
CD8+ T cells in brain parenchyma in close proximity to
neurons and astrocytes has pointed to a role for major
histocompatibility complex (MHC) class I-restricted
CD8+ cytotoxic T cells in RE [12]. The cytotoxic T cells
are likely reacting to foreign or self-antigens displayed
by neurons and astrocytes in the affected cerebral hemi-
sphere. Confinement of the T cells to one cerebral hemi-
sphere suggests that the initial inflammatory reaction
may have been spatially restricted. Such a reaction would
have triggered a localized innate immune response by
brain resident macrophages (microglia) and could have
led to the recruitment of nonresident non-MHC-
restricted immune cells, such as natural killer cells and
γδ T cells followed by primed MHC-restricted αβ T cells.
In the present study, we document for the first time the
presence of clonally restricted γδ T cells in brain tissue
from RE patients, indicating a role for this T cell subtype
in the inflammatory response in RE.
Methods
RE patient cohort and clinical variables
Under the University of California, Los Angeles, Institu-
tional Review Board (UCLA IRB) approval (IRB #11-
00030), brain tissue and blood were collected at surgery
as part of UCLA’s Pediatric Epilepsy Surgery Program.
For cases that were not treated at UCLA, tissue and
blood were provided to UCLA under the auspices of the
UCLA IRB approved Rare Brain Disease Tissue Bank(IRB# 13-001213). All of the patients or their parents or
legal guardians provided informed consent for the use of
the surgical remnant and blood for research purposes.
All specimens were collected using the same standard
operating procedures (SOPs); SOPs were provided by
UCLA to the contributing institutions. De-identified pa-
tient information was collected with informed consent
including age at seizure onset, age at surgery, gender,
and affected cerebral hemisphere.
Isolation of peripheral blood lymphocytes and brain-
infiltrating lymphocytes
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient centrifugation using Ficoll-Paque
PLUS (GE Healthcare, Piscataway, NJ). Brain-infiltrating
lymphocytes (BILs) were isolated from collagenase-treated
brain tissue by fractionation on a step gradient. Briefly,
brain tissue was diced manually on ice in dissociation so-
lution (HBSS with 20 mM HEPES pH 7.0, 5 mM glucose,
and 50 U/ml penicillin/streptomycin). Tissue fragments
were incubated with agitation in dissociation solution con-
taining 0.5 mg/ml type IV collagenase (Worthington Bio-
chemical Corp., Lakewood, NJ) and 5 % filtered human
serum (Mediatech Inc., Manassas, VA) at 37 °C for 3 h
or at room temperature overnight. The dissociated tissue
was fractionated on a 30:70 % Percoll® (SigmaAldrich, St.
Louis, MO) step gradient in RPMI containing 20 mM
HEPES. PBMCs and BILs were cryopreserved in 90 % hu-
man serum/10 % DMSO.
Analysis of lymphocytes by flow cytometry
Phenotypic data were acquired on an analytical LSRII
flow cytometer (Becton Dickinson, San Jose, CA). The
following antibodies were used: APC-efluor® 780-
conjugated CD3 (clone UCHT1; eBioscience Inc., San
Diego, CA), PE/Cy7-conjugated CD4 (clone SK3;
eBioscience Inc.), PerCP/Cy5.5-conjugated CD8 (clone
RPA-T8; eBioscience Inc.), APC-conjugated T cell receptor
(TCR) αβ (clone IP26; eBioscience Inc.), FITC-conjugated
TCR γδ (clone B1.1; eBioscience Inc.), PE-conjugated
CD69 (clone FN50; eBioscience Inc.), PE-conjugated TCR
Vδ2 (clone B6; Biolegend), and FITC-conjugated TCR
Vδ1 (Clone TS8.2; GeneTex Inc., Irvine, CA). Data were
analyzed with FlowJo software (TreeStar Inc., Ashland,
OR); plots were exported to CorelDRAW X6 (Corel
Corporation, Ottawa, Canada). Statistical analyses and
graphing utilized R-project programs (www.r-project.org).
Spectratyping T cell receptor Vδ chains
Total RNA was purified from flash frozen blocks of in-
volved tissue consisting of mostly cortical gray matter
(~50 mg) using Trizol™ (Life Technologies, Carlsbad,
CA) followed by column purification (Qiagen, Valencia,
CA). RNA was reverse transcribed (Qiagen), and PCR
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(ABI) GeneAmp® PCR system 9700 using AccuPrime™
Taq polymerase (Life Technologies). The same primer
sets described by Dechanet et al. [13] were used; forward
primers were unique to Vδ1, Vδ2, and Vδ3, respectively,
and two nested reverse primers were located in the con-
stant region. The sequences of each primer are as fol-
lows: Vδ1 5′ CTGTCAACTTCAAGAAAGCAGCGAA
ATC 3′; Vδ2 5′ TACCGAGAAAAGGACATCTATGGC
3′; Vδ3 5′GGGGATAACAGCAGATCAGAAGGT 3′;
Cδ1.1 5′ TGGGAGAGATGCAATAGCAGGATC 3′;
Cδ1.2 5′ ACGGATGGTTTGGTAGAGGCTGA 3′. The
Cδ1.2 primer was end-labeled with 6-carboxyfluorescein
(FAM). The cycling conditions were as follows: 94 °C
2 min followed by 40 cycles of 94 °C 45 s, 60 °C 45 s,
68 °C 45 s, and a run off step at 68 °C for 4 min. For the
second round of PCR, the number of cycles was reduced
to 35 cycles. FAM-labeled products were separated on
an ABI 3730 Capillary DNA Analyzer (Life Technolo-
gies), and peak areas were calculated using ABI Peak
Scanner Software 2 (Life Technologies). In order to
compare the relative amounts of each Vδ chain-specific
fragment between samples, areas of individual peaks in
each sample were normalized to the total peak area in
each sample. Data were clustered and displayed as a
heat map using the GENE-E bioinformatics package
(www.broadinstitute.org).
DNA sequencing T cell receptor Vδ CDR3s
First round Vδ2 and Vδ3 PCR fragments that yielded a
single FAM-labeled fragment were re-amplified with the
appropriate chain-specific forward primer and an un-
labeled Cδ1.2 reverse primer. PCR products were treated
with ExoSAP-IT (Affymetrix, Inc. Santa Clara, CA) and
sequenced by the Sanger sequencing method using Big-
Dye® cycle sequencing chemistry (Life Technologies).
Sequences were analyzed using International Immuno-
genetics Information System (IMGT)/V-QUEST, the
IMGT web portal for analysis of T cell receptor and im-
munoglobulin sequences [14]. To sequence Vδ1 frag-
ments, adaptors were added to the first round PCR
products in the second PCR step, and the resulting
DNA fragments were separated by agarose gel electro-
phoresis and purified (Qiagen). The following primers
were used (TCR sequences are underlined): Vδ1
adaptor (forward primer) 5′ GAGACAGTCGTCGG
CAGCGTCAGATGTATAACTGTCAACTTCAAGAA
AGCAGGAAATC 3′; Cδ1.2 adaptor (reverse primer) 5′
GTCTCGTGGGCTCGG AGATGTGTATAAGAGACA
GACGGATGGTTTGGTAGAGGCTGA 3′. Nextera
XT indices (Illumina, San Diego, CA) were added by
tagging PCR using a KAPA Hifi PCR kit (KAPA Biosys-
tems, Boston, MA), and the PCR products were purified
using the Agencourt AMPure XP system (BeckmanCoulter, Brea, CA). Fragments were sized on a Bioanalyzer
instrument (Agilent Technologies, Inc. Santa Clara, CA),
quantified by qPCR (KAPA library quant kit), and pooled.
Libraries were sequenced on a MiSeq desktop sequencer
using V2 2 × 250 bp chemistry (Illumina). IMGT/HighV-
QUEST, the IMGT web portal for high throughput ana-
lysis of T cell receptor and immunoglobulin sequences
was used to curate all of the sequence data [14]. Scripts
were written in R and Python to collate and enumerate
the sequences. The δ1-specific sequences from cortical
dysplasia (CD) brain samples were generated as described
above. In the second PCR step, CDR3 clone-specific for-
ward primers were used together with an extended Cδ1.1
primer, 5′ CTGGGAGAGATGACAATAGCAGGATCAA
ACTCTG 3′. The following forward primers were used:
CDR3 ALGDSIPRRIAYTDKLI, 5′ GCTCTTGGGGATT
CCATTCCTAGGAGGATAGCGTACACCGATAAACTC
ATC 3′; CDR3 ALGGLGTGGYAYTDKLI, 5′ GCTCTT
GGGGGGCTAGGTACTGGGGGATACGCCTACACCG
ATAAACTCATC 3′; CDR3 ALGVPPRPSLYWGIGSLG-
SYTDKLI, 5′ GCTCTTGGGGTCCCGCCTCGACCTTC
CCTCTACTGGGGGATAGGAAGCTTGGGCTCGTAC
ACCGATAAACTCATC 3′. The cycling conditions were as
follows: 94 °C 2 min followed by 35 cycles of 94 °C 45 s, 68 °
C 90 s, and a run off step at 68 °C for 4 min. PCR products
were gel purified and sequenced by the Sanger sequencing
method using BigDye® cycle sequencing chemistry (Life
Technologies). Sequences were aligned in Seaview [15].
Immunocytochemistry
Surgical tissue blocks were fixed in freshly prepared 4 %
paraformaldehyde in phosphate-buffered saline (PBS) for
24–48 h, then cryoprotected by immersion overnight at
4 °C in 20 % sucrose-PBS followed by 30 % sucrose-PBS.
Blocks were then frozen with powdered dry ice and
stored at −80 °C. Immunostaining was performed on
free-floating 30-μm cryostat-cut sections by first block-
ing in PBS with 5 % normal goat serum (Vector Labora-
tories, Burlingame, CA) and 0.3 % Triton X-100 for 1 h.
Sections were then incubated in mouse anti-human TCR
pan γδ (clone 5A6.E9, 1:100, Thermo Scientific, Waltham,
MA) and an anti-human CD3 rabbit polyclonal antibody
(1: 100, Dako North America, Inc. Carpinteria, CA) over-
night at 4 °C followed by incubation in Alexa Fluor® 488
goat anti-rabbit and Alexa Fluor® 568 goat anti-mouse sec-
ondary antibodies (1:1000, Life Technologies) for 1 h at
room temperature. Sections were mounted on slides and
cover-slipped using ProLong® Gold anti-fade reagent con-
taining DAPI (Life Technologies). Fluorescent images
were acquired with an Olympus spinning disk confocal
microscope (Olympus America, Inc., Center Valley, PA)
controlled by SlideBook™ image acquisition and analysis
software (Intelligent Imaging Innovations, Inc. Denver
CO). Images were transferred to CorelDRAWX6 (Corel
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volved tissue were deparaffinized and microwaved for
20 min in buffered citrate (10 mM, pH 6.0) to retrieve
antigens. After blocking for 1 h (Impress Kit, Vector La-
boratories, Burlingame, CA), sections were incubated
overnight at 4 °C with rabbit anti-human CD3 (1:800,
Dako) or mouse anti-human CD69 (clone CH11, 1:50,
Abcam, Cambridge, MA). Peroxidase-conjugated anti-
rabbit or anti-mouse secondary antibodies (1: 300; Im-
press Kit, Vector Laboratories) were added for 1 h at
room temperature, followed by incubation with 3,3′-di-
aminobenzidine (DAB) substrate (MP Biomedicals,
Santa Ana, CA) and subsequent counterstaining with
hematoxylin. Omission of primary antibodies served as
negative controls. Images of the entire sections were ac-
quired with an Aperio ScanScope XT scanner (Aperio,
Vista CA) and transferred to CorelDRAWX6 (Corel
Corporation).
Results
RE patient cohort and collection of surgical specimens
Table 1 provides details of the RE patient cohort used in
this study. There were no exclusion criteria. Blood was
drawn from the arterial line prior to initiating the sur-
gery. Brain tissue was placed into ice-cold Hibernate®
medium immediately after resection. Samples of brainTable 1 Clinical data from 20 RE patients





RECP20 F 3 6.1 L
RECP21 M 8 11.9 L
RECP24 F 1.3 2.1 L
RECP25 M 8.3 14.9 L
RECP26 F 6 14.4 L
RECP27 F 7.8 8 R
RECP28 F 9 10 L
RECP29 M 10 13 R
RECP30 F 6 7.9 R
RECP31 M 6 9 R
RECP32 F 8 11 L
RECP33 M 4.3 5.8 L
RECP34 M 9 10.9 R
RECP35 F 4.5 6 L
RECP36 M 6 8 R
RECP37 F 3 3.3 R
RECP39 M 11 12 R
RECP42 F 3 4 L
RECP43 F 7 9.4 L
RECP46 F 6.2 6.7 Ltissue and blood were sent to UCLA in shipping con-
tainers that kept the samples at 4 °C.
Brain-infiltrating CD3+ cells are predominantly of CD8+
αβ+ and CD4− CD8− γδ+ T cells
To isolate BILs, fresh surgical specimens were digested
with collagenase and fractionated on Percoll™ step gradi-
ents. CD3+ lymphocytes were compared with those in
peripheral blood collected from the patients at the time
of surgery. Cells were isolated and immunostained at dif-
ferent times because specimens were acquired over a
period of 30 months. However, every effort was made to
standardize all of the procedures. The yield of BILs var-
ied between samples and was largely dependent upon
the amount of tissue obtained.
BILs and PBMCs were gated on CD3, CD4, CD8, αβ,
and γδ T cell markers. In each case, the percent of αβ T
cells was higher in the PBMC compared to the BIL frac-
tion (Fig. 1a); however, BILs contained significantly more
γδ T cells, which were mainly CD4− CD8− (Fig. 1b; Add-
itional file 1: Table S1). The median ratio of αβ:γδ T cells
was 1.9 (range 0.58–5.2) in the BIL fractions, compared
with a median ratio of 7.7 (range 2.7–40.8) in PBMCs
(Additional file 1: Table S1). αβ T cells were predomin-
antly CD8+ in the BIL populations, confirming previous
immunocytochemical studies [12, 16–18] (Fig. 1c). The
percentage of γδ T cells in the BIL fractions was not sig-
nificantly correlated with the age at which the patient
presented with seizures, nor the length of time between
seizure onset and surgery (p = 0.7731 and p = 0.1913,
respectively).
Both αβ and γδ T cells in the BIL fractions analyzed
(n = 14) expressed the early activation marker CD69 in-
dicating that an active immune reaction involving both
T cell subtypes was taking place at the time of surgery in
the affected cortical hemisphere of these patients. The
percent of activated αβ and γδ T cells was highly corre-
lated (Fig. 1d). CD69 expression by infiltrating T cells
was confirmed by immunocytochemistry using a second
CD69 antibody (Additional file 2: Figure S1).
Figure 2 shows two examples of the distribution of γδ
T cells in involved cortical tissue. In Fig. 2a, b, perivascu-
lar T cells appear to be predominantly γδ T cells,
whereas in Fig. 2d, e, γδ T cells form only part of a large
cluster of T cells within brain parenchyma. The other T
cells in this cluster are likely to be CD8+ αβ T cells.
A restricted repertoire of γδ T cells in RE brain tissue
To gain insight into the T cell receptor (TCR) repertoire
of brain-infiltrating γδ T cells, RNA was extracted from
flash frozen brain tissue obtained from 14 of the 20 RE
cases previously analyzed by flow cytometry. The RNA
was transcribed into cDNA and was used as a template



































































Fig. 1 Phenotypic analysis of CD3+ T cell subsets in brain-infiltrating lymphocytes (BILs) and in peripheral blood mononuclear cells (PBMCs) from
RE patients. The proportion of each T cell subtype as a percentage of the number of CD3+ cells gated in each sample is shown. a Stacked dot
plot showing the percent of αβ T cells in BILs (red dots n = 20) compared with PBMCs (blue dots) from the same cases (p = 0.0001, pair-wise
Wilcoxon signed-rank test). b Stacked dot plot showing the percent of TCR γδ T cells in BILs compared with PBMCs from the same patients
(p = 0.0001, pair-wise Wilcoxon signed-rank test). c Stacked dot plot showing the ratio of CD4+ αβ:CD8+ αβ T cells in BILs compared with the
corresponding PBMCs (p = 0.0001, pair-wise Wilcoxon signed-rank test). d Plot of the percent of CD69+ αβ T cells versus CD69+ γδ T cells in BIL
fractions (n = 14; r = 0.9547, CI 0.8595, 0.9859, p < 0.0001). Additional file 1: Table S1 provides the quantitative data
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Vδ3) to within the common constant region, thus span-
ning the third complementarity determining region
(CDR3), a major determinant of γδ TCR specificity [19].
Fragment lengths differed due to variable D and J seg-
ment usage and nucleotide addition and trimming [20].
The heat map in Fig. 3 presents the results of the spec-
tratyping where the different colors denote the relative
amounts of each PCR product within a sample. Based
on the number of fragments of different sizes, it appears
that the repertoire of Vδ chains among the RE samples
is relatively restricted. In several cases, only a single
amplified product was obtained with the Vδ2- and Vδ3-
specific primers (RECP25, RECP29, RECP31, RECP33
for Vδ2, and RECP26 for Vδ3) indicating the presence
of single clones. These products were sequenced and, as
expected from the size differences, encoded differentCDR3 sequences (Additional file 3: Table S2). Compared
to the number of Vδ1 fragments, there were fewer Vδ2-
or Vδ3-specific products in each sample; several Vδ2 or
Vδ3 fragments of the same size were found in over half
of the samples. Four of the Vδ1 fragments (183, 186,
198, and 204 bp) were found in all of the samples, and a
further three Vδ1 fragments (189, 195, and 201 bp) were
found in 13/14 samples. One or more of these seven
products were highly expressed in all of the samples,
suggesting that they may represent the dominant Vδ1-
containing γδ T cell clones in these RE cases. Staining
BILs from two of the RE cases (RECP26 and RECP33)
with Vδ1- and Vδ2-specific antibodies showed that
≥90 % of the γδ T cells expressed Vδ1, suggesting that δ1
clones may be highly represented in the populations of γδ
T cells in RE brain tissue. As expected, the corresponding
PBMCs were ≥77 % Vδ2+ (Fig. 4) [21].
Fig. 2 Identification of γδ T cells in RE brain parenchyma by immunofluorescence microscopy. Sections of cortex from a RE hemispherectomy
surgery were co-stained with a polyclonal CD3 antibody and a pan TCR γδ mAb. CD3 staining was visualized with an Alexa Fluor® 568 secondary
antibody (a. d), and TCR γδ staining with an Alexa Fluor® 488 secondary antibody (b. e). c, f Merged images. Scale bars correspond to 100 μm
Owens et al. Journal of Neuroinflammation  (2015) 12:134 Page 6 of 12Identical Vδ1 CDR3 sequences in RE brain tissue
All of the Vδ1-specific PCR products were sequenced.
DNA sequences were curated by submitting them to the
IMGT/HighV-QEST web portal [14]. Several thousand
different δ1 clonotypes were identified in each sample as
defined by differences in the amino acids in the V gene
segment that contribute to CDR3 (amino acids 105–108
according to the IMGT standardized numbering system)
and by D and J gene segment usage [20]. Strikingly, less
than 20 clonotypes were found at a frequency of >1 % in
each sample, and these accounted for 64–83 % of the
clonotypes in each sample (Table 2). In order to tabulate
the frequency of each clonotype in every sample and to
determine the extent of overlap, a matrix was constructed
for all of the clonotypes found at a frequency of >1 %.
As shown in Fig. 5 and in Additional file 4: Table S3, 49
different clonotypes accounted for all of the clonotypes
found at >1 % frequency in all of the samples. This indi-
cates that there may be common antigenic targets rec-
ognized by these relatively abundant γδ T cell clones.
To obtain further evidence for this supposition, the
CDR3 amino acid sequences of four dominant clono-
types (Fig. 5 bold-faced type) were examined. Each clo-
notype comprised several thousand different CDR3
sequences as a result of nucleotide addition and trim-
ming during somatic rearrangement of the TCR gene
segments. For each of the four clonotypes, the mostfrequent CDR3 sequence in each sample was tabulated
and compared. For three of the clonotypes, the same
CDR3 sequences were found in all of the samples, albeit
at varying frequencies (Fig. 6; Additional file 5: Table
S4). Strikingly, the most frequent CDR3 sequence in
one of the clonotypes was the same in all of the samples
(Fig. 6; Additional file 5: Table S4). These CDR3 se-
quences were not found in a BLAST search of the
IMGT database.
The identical δ1 CDR3 sequences are detected in
dysplastic cortical tissue
To determine whether the dominant δ1 clones that we
had identified were specific to RE, we designed CDR3
sequence specific PCR primers. We selected the three
dominant clonotypes in which a single CDR3 amino se-
quence predominated (Additional file 5: Table S4). DNA
sequences were ranked according to their frequency of
occurrence in each RE sample. For each CDR3, a PCR
primer was synthesized based on the DNA sequence that
was found at the highest frequency in the majority of
the samples (Additional file 6: Table S5). We tested the
primers on RNA extracted from brain specimens from
15 focal cortical dysplasia (FCD) type I surgical cases
[22] (Additional file 7: Table S6). Markers of inflamma-
tion, including T cells, have been previously detected
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Fig. 3 Heat map summarizing the spectratyping of Vδ chains in brain tissue from 14 RE patients. Sequences specific to the three major Vδ chains
were amplified by nested PCR and separated by capillary electrophoresis. For each of the 14 RE samples and for each chain-specific primer, the
area of each peak corresponding to a different fragment length was expressed as a fraction of the total area under the peaks and converted into
a heat map. The data for each Vδ chain were clustered to show which samples were more related to each other based on the fragment lengths,
which are listed above each heat map. RNA was extracted from samples of flash frozen brain tissue
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were in approximately the same age range as the RE cases
(Additional file 7: Table S6). As summarized in Fig. 7 and
Additional file 8: Figure S2, sequences identical to those
found in the RE samples were detected, demonstrating
that the δ1 clones are not unique to RE.Discussion
With the participation of eleven other institutions, we
accrued fresh brain specimens from 20 RE surgeries over
a 2.5-year period. We have carried out an initial
characterization of T cells isolated from these specimens
in comparison with T cells in peripheral blood from the
Table 2 Evidence for a limited number of highly expressed δ1
clonotypes in each RE brain specimen















Sequences were assigned to individual clonotypes based on amino acid
changes in the residues of the V gene segment that contribute to the CDR3
and D and J gene segment usage. The frequency of each clonotype was
calculated. The number of clonotypes >1 % of the total were tabulated, and
the frequencies of these clonotypes were summated to give the percentage of































Fig. 4 Expression of T cell receptor (TCR) Vδ1 and Vδ2 chains by γδ
T cells in brain-infiltrating lymphocytes (BILs) and peripheral blood
mononuclear cells (PBMCs) from two RE patients. BILs and PBMCs
from two RE cases were stained with CD3, CD4, CD8, TCR αβ, TCR
Vδ1-, and TCR Vδ2-specific antibodies. CD3+ CD4− CD8− PBMCs are
predominantly Vδ2+ (76.7 and 79.8 % for RECP26 and RECP33,
respectively), whereas most CD3+ CD4− CD8− BILs express Vδ1
(89.8 and 97.1 % for RECP26 and RECP33, respectively). The number
of CD3+ BILs gated was 1887 for RECP26 and 1516 for RECP33
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were made. The profile of brain-infiltrating CD3+ T cells
was relatively consistent, comprising mostly CD8+ αβ and
CD4− CD8− γδ T cells with fewer CD4+ αβ T cells,
whereas the profile of peripheral blood, collected at the
time of surgery, was more variable. The predominance of
CD8+ T cells in the BIL populations agrees with published
immunohistochemistry results [12, 16–18], but the pres-
ence of γδ T cells is a new finding and has implications for
the immune response in RE. This T cell subtype acts like
an innate immune cell and plays an important role in both
tumor and pathogen immune surveillance [24, 25]. γδ T
cells are mainly found in the skin, gut, lungs, and genito-
urinary tract and normally comprise only a small fraction
of circulating T lymphocytes [26, 27]. Unlike αβ T cells, γδ
T cells recognize intact antigens and are not dependent on
antigen presentation by classical MHC molecules [19,
28]. They recognize transformed and infected cells via
NKG2D- and TCR-dependent binding [29]. Stress-
induced self-proteins related to MHC molecules, lipid
moieties bound to CD1 proteins, heat shock proteins,
and phosphorylated metabolites made by certain patho-
gens and tumor cells are recognized by γδ T cells
[19, 28].
Vδ spectratyping showed that γδ T cells in RE brain
tissue were oligoclonal and revealed the presence of
dominant clonotypes. Vβ spectratyping has also provided
evidence for oligoclonality of αβ T cells in RE [30, 31].
Strikingly, the same CDR3 sequences in four abundant δ1
clonotypes were highly represented in every sample. This
finding strongly indicates that in all of the RE cases ana-
lyzed, and possibly in all RE cases, there are clones of γδ T
cells that recognize the same epitope(s). In a study of un-
related newborns who had been infected in utero with
cytomegalovirus, T cells with identical TCR Vδ1 CDR3 se-
quences were found in the blood of every infected individ-
ual [32]. It is thought that convergent recombination
primarily accounts for the development of public T cell
clones [33].
The antigen(s) recognized by γδ T cells in RE are cur-
rently unknown. As mentioned above, CD1 proteins are
ligands for γδ TCRs. The structures of two different δ1
TCRs complexed with CD1d-bound sulfatide and CD1d-
bound α-galactocerebroside, respectively, were recently
determined [34, 35]. Two CDR3 motifs, YWG and TDK,
that were found to directly interact with residues in
CD1d are present in several of the clones that we se-
quenced (Fig. 6), suggesting the possibility that some γδ
T cells in RE brain may bind CD1d. In addition, one of
the prevalent CDR3 sequences that we identified con-
tains the heptapeptide motif (AYTDKLI) that is also
found in a δ1-containing TCR that binds a stress regu-
lated, MHC class I related molecule, MHC class I poly-
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G107E E108P 3 1
G107E E108R 3 1
G107E E108V 2,3 1
G107E E108V 3 1
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Fig. 5 Frequency of δ1 clonotypes present at >1 % in RE brain tissue. PCR fragments amplified with a Vδ1-specific forward primer were
sequenced on a MiSeq DNA sequencing platform. Sequences were assigned to individual T cell clonotypes based on three criteria: (1) nucleotides
coding for the last four amino acids of the variable (V) region, which contribute to the third complementarity determining region (the IMGT
algorithm lists amino acid changes with respect to a reference Vδ1 sequence, which is shown in the figure, (2) the number and identity of
diversity (D) gene segments, and (3) the identity of the joining (J) gene sequences. There are three possible D gene segments and four possible J
gene segments. Clonotypes were selected from each sample that comprised >1 % of the total repertoire in each sample. Collectively, these 49
clonotypes made up more than 70 % of the repertoire of γδ T cells expressing Vδ1 in each of the RE brain tissue samples. Of these, several
dominant clones were evident (bold-faced type). A heat map was generated from the quantitative data; the vertical columns show the relative
abundance of each clonotype in each sample. The data are clustered to show which cases have the most similar repertoires. Additional file 3:
Table S3 shows the quantitative data
Owens et al. Journal of Neuroinflammation  (2015) 12:134 Page 9 of 12possible to derive clonal lines of γδ T cells from the RE
BIL fractions and use binding assays to determine if they
interact with these non-classical MHC class I molecules.
Using PCR primers designed to amplify the δ1 CDR3
region from three of the dominant clones, we detectedthe same sequences in dysplastic brain tissue. The PCR
detection method used was not quantitative; thus, we do
not yet know how prevalent these δ1 clones are in FCD
brain. Further analysis of the γδ T cell repertoire in FCD
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Fig. 6 Identical Vδ1 CDR3 sequences in dominant clonotypes present in RE brain tissue. CDR3 sequences of four dominant clonotypes were
analyzed, and the most frequent CDR3 sequence in each sample was determined for each clonotype. Identical sequences were found in every
sample for three of the clonotypes. The shaded amino acid is the last residue encoded in the V gene segment. A heat map was generated from
the quantitative data; the rows show the relative abundance of each CDR3 sequence in each sample. Additional file 4: Table S4 provides the
quantitative data
Owens et al. Journal of Neuroinflammation  (2015) 12:134 Page 10 of 12studies. The finding of γδ TCR sequences is not entirely
unexpected as the presence of T cells in FCD brain has
been reported [23]. Finding the same δ1 clones in RE
and FCD is also consistent with reports of dual
pathology [37–42]. Whether the γδ T cell clones that we
have identified are only associated with inflammatory
events in RE and FCD remains to be determined. If they
can be detected in peripheral blood, then they might be
useful as a diagnostic indicator of RE, FCD, or brain in-
flammation in general.
Both RE and FCD are associated with seizures, which
have been shown to promote an inflammatory reaction
in the brain [43]. γδ T cells are likely to be among the
first immune cells to cross the blood brain barrier in re-
sponse to pro-inflammatory cytokines such as IL-1β and
IL-18 released by inflammasomes [43, 44]. The presence
of inflammasomes associated with microglia in RE brain
tissue has recently been described [45]. In response to
inflammatory cytokines, γδ T cells can act as an innate
immune cell and release inflammatory cytokines in par-
ticular IL-17 without TCR engagement potentially per-
petuating an inflammatory reaction [46].
In RE, γδ T cells may provide a link between inflam-
mation in the brain and an adaptive immune response
involving antigen-specific CD8+ T cells. In multiple








Fig. 7 Vδ1 CDR3 sequences in dominant clonotypes are detectable in rese
the most prevalent DNA sequences that specified the CDR3 regions of thre
products were sequenced. A red square denotes the presence of a sequenc
are shown in Additional file 8: Figure S2predominantly IL-17+, linking this functional subtype to
autoimmunity [46–48]. On the other hand, they can act
as an adaptive immune cell and bind a cognate antigen
and produce IFN-γ [49]. Neurons and astrocytes that ex-
press specific stress-induced autoantigens might be dir-
ectly engaged by Th1-polarized γδ T cells. In mice, the
costimulatory receptor CD27 is expressed by IFN-γ+ but
not IL-17+ γδ T cells [50]. Immunostaining BILs with
CD27 antibodies may allow us to differentiate between
these two functional types of γδ T cells in RE brain tis-
sue. Th1 cytokines such as IFN-γ released by γδ T cells
would also be expected to promote a cytotoxic CD8+ αβ
T cell response [51]. IFN-γ increases MHC class I on
neurons, which would render them selectively vulnerable
to CD8+ cytotoxic αβ T cells [52]. γδ T cells may also
play an immunosuppressive role depending upon the
stage of the disease, as appears be the case in multiple
sclerosis [47]. Multiple roles for γδ T cells in RE
might explain why the percentage of γδ T cells in CD3+
BILs isolated at the time of surgery appeared to be un-
related to the length of time between seizure onset and
surgery.
The cause of RE is unknown. A role for predisposing
genetic factors that would influence the outcome of an
immune response resulting from seizure-induced inflam-











cted cortical dysplasia brain tissue. Primers were designed based on
e of the dominant δ1 clonotypes identified in RE brain tissue. PCR
e, and an open square indicates its absence. Aligned DNA sequences
Owens et al. Journal of Neuroinflammation  (2015) 12:134 Page 11 of 12also be involved in the etiology of RE [4–7, 53, 54],
which would fit with the known role of γδ T cells in
pathogen surveillance. In a separate RNAseq study, we
have looked for evidence of a persistent viral infection in
resected RE brain tissue but have not found any gene
transcripts encoded by known viruses (unpublished re-
sults). In the absence of a persistent infection, RE could
involve T cells that recognize an epitope common to
both a foreign and a self-antigen, T cells that express
dual receptors, or epitope spreading [55–58].Conclusions
The cellular immune response in RE involves both clas-
sical αβ T cells and non-classical γδ T cells. The γδ T
cells appear to be clonally restricted, and prevalent
clones may recognize a common antigen(s), possibly a
self-antigen associated with stressed cells. γδ T cells may
facilitate the activation of auto-reactive αβ T cells by
releasing pro-inflammatory cytokines and promoting
antigen presentation. The presence of the identical δ1
subtype clones in CD brain implies the involvement of
a common inflammatory pathway in both diseases.Additional files
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